Contravisory Investment Management’s VeriSign VRSN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-2,362
Closed -$660K 430
2025
Q3
$660K Sell
2,362
-12
-0.5% -$3.35K 0.13% 118
2025
Q2
$686K Sell
2,374
-27
-1% -$7.32K 0.13% 106
2025
Q1
$610K Buy
+2,401
New +$546K 0.13% 112
2023
Q3
Sell
-1,576
Closed -$356K 392
2023
Q2
$356K Buy
+1,576
New +$347K 0.09% 152
2022
Q2
Sell
-387
Closed -$86K 379
2022
Q1
$86K Buy
+387
New +$84.4K 0.02% 229
2020
Q1
Sell
-2,837
Closed -$547K 324
2019
Q4
$547K Sell
2,837
-13
-0.5% -$2.44K 0.2% 55
2019
Q3
$538K Sell
2,850
-24
-0.8% -$4.93K 0.2% 51
2019
Q2
$601K Buy
2,874
+2
+0.1% +$393 0.23% 48
2019
Q1
$521K Sell
2,872
-56
-2% -$9.61K 0.2% 53
2018
Q4
$434K Buy
2,928
+124
+4% +$18.6K 0.19% 58
2018
Q3
$449K Sell
2,804
-14
-0.5% -$2.15K 0.16% 70
2018
Q2
$387K Buy
2,818
+2,781
+7,516% +$357K 0.14% 86
2018
Q1
$4K Buy
+37
New +$4.29K ﹤0.01% 311
2016
Q4
Sell
-193
Closed -$15K 327
2016
Q3
$15K Buy
+193
New +$15.5K ﹤0.01% 172

Other funds holding VRSN

Contravisory Investment Management's VRSN Position: Q4 2025 in Review

Contravisory Investment Management sold out of VeriSign (VRSN) in Q4 2025, closing a stake of 2,362 shares — an estimated $660K sold.

Contravisory Investment Management first reported a position in VRSN in Q3 2016 and held it in 14 quarters. The position peaked at $686K in Q2 2025. 852 funds tracked by Wall St. Rank hold VRSN as of Q4 2025.

  • Contravisory Investment Management reported no remaining VeriSign position as of Q4 2025 after selling out during the quarter.
  • Contravisory Investment Management sold 2,362 VeriSign shares in Q4 2025, an estimated $660K.
  • Contravisory Investment Management first reported a position in VeriSign in Q3 2016 and held it in 14 quarters.
  • Contravisory Investment Management's VeriSign position peaked at $686K in Q2 2025.
  • 852 funds tracked by Wall St. Rank held VeriSign as of Q4 2025.

Based on Contravisory Investment Management's 13F filing for Q4 2025, filed 12 Jan 2026.